Bayer Halts Essure Sales In EU As US FDA Relies On Study, Patient Warnings
Bayer AG said Sept. 18 it will not renew a CE mark for its Essure permanent contraceptive coils for women in EU countries, effectively halting sales of the product outside the US. The firm says its decision was "unrelated to product safety or efficacy," and driven by its commercial strategy. Meanwhile, US FDA calls for warnings and black box labels for Essure in the US, and says a Sec. 522 post-market study it ordered Bayer to complete "will help us better understand" thousands of complaints about the device.
You may also be interested in...
FDA’s Device Center Could Raid $2.8M From Staff Outreach, Training Kitty In 2021 To Fund Other CDRH Needs
While the Trump administration’s proposed fiscal year 2021 budget for the US FDA would give the agency’s device center a 5.3% increase for medtech product approvals and safety, the center’s lofty plans to become the world’s premier regulator of new AI-driven gadgets, next-gen diagnostics and other novel devices means it will have to tap about $2.8m dollars usually set aside for staff training and outreach to help meet its ambitious goals.
US FDA is placing more restrictions on the sale of Bayer's Essure permanent contraception device by requiring both patients and providers to read and sign off on a patient checklist highlighting adverse events.
Product liability suits involving Bayer's Essure contraceptive device are moving forward in California state courts despite rulings that dismissed some of the plaintiffs' claims.